Q-omics provides the consensus-scored MTG1 profile across patient tissues and cancer cell-line models. MTG1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MTG1 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, MTG1 RNA expression shows 19,900 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, COAD, and ACC as cancer lineages where MTG1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTG1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTG1 survival associations across molecular data types. MTG1 RNA expression shows survival associations in the most cancer types (23), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTG1 RNA expression–survival associations across cancer types. High MTG1 expression shows unfavorable associations in UVM, ACC, KIRC and COAD, but favorable associations in BLCA and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for MTG1 RNA expression.
This table summarizes MTG1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MTG1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTG1 shows lower tumor expression in KICH and higher tumor expression in COAD, BLCA, LIHC, STAD and LUAD. The COAD box plot shows higher MTG1 RNA expression in tumor versus normal tissue (log2 FC = +0.753, t-test p < 0.001).
This table shows molecular features associated with MTG1 in patient tissues and cancer cell lines. In patient samples, MTG1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MTG1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Lymphoma.
